title: Effects of three different medications on metabolic parameters and testicular volume in patients with hypogonadotropic hypogonadism: 3-year experience.
abstract: BACKGROUND
  The aim of this study was to demonstrate the influences of three different treatment strategies on biochemical parameters and testicular volume (TV) in patients with idiopathic hypogonadotropic hypogonadism (IHH).
  Seventy-seven never-treated patients with IHH and age and body mass index (BMI)-matched 42 healthy controls were analysed in a retrospective design. Twenty-eight patients were treated with testosterone esters (TE), 25 patients were treated with human chorionic gonadotropin (hCG) and 24 patients were treated with testosterone gel (TG). Biochemical parameters, tanner stages (TS) and TV were evaluated before and after 6 months of treatment.
  
  
  RESULTS
  Pretreatment TV, TS and biochemical test results were similar among the three treatment subgroup. In the TE-treated group, BMI, haemoglobin, haematocrit, creatinine, triglyceride, total testosterone (TT), TS and TV increased, but HDL-cholesterol (C) and urea level decreased significantly. In the hCG-treated group, triglyceride level decreased, and luteinizing hormone level, TS and TV increased significantly. BMI, TT, TS and TV increased, and leucocyte count, total-C, HDL-C levels decreased significantly in the TG-treated patients. No treatment type resulted in any changes in insulin resistance markers.
  
  
  CONCLUSIONS
  hCG treatment resulted in favourable effects particularly on TV and lipid parameters. When TV improvement is considered less important, TG treatment may be a better option for older patients with IHH because of its easy use, neutral effects on triglyceride, haemoglobin and haematocrit, and its beneficial effects on total cholesterol level.
authors.affiliation: Department of Endocrinology and Metabolism, Gulhane School of Medicine, Ankara, Turkey. draydoganaydogdu@gmail.com
authors.forename: Aydogan
authors.initials: A
authors.lastname: Aydogdu
authors.forename: Erol
authors.initials: E
authors.lastname: Bolu
authors.forename: Alper
authors.initials: A
authors.lastname: Sonmez
authors.forename: Ilker
authors.initials: I
authors.lastname: Tasci
authors.forename: Cem
authors.initials: C
authors.lastname: Haymana
authors.forename: Ramazan
authors.initials: R
authors.lastname: Acar
authors.forename: Coskun
authors.initials: C
authors.lastname: Meric
authors.forename: Abdullah
authors.initials: A
authors.lastname: Taslipinar
authors.forename: Taner
authors.initials: T
authors.lastname: Ozgurtas
authors.forename: Omer
authors.initials: O
authors.lastname: Azal
mesh_terms: D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D009929:Organ Size; D012189:Retrospective Studies; D013737:Testis / Q000033:anatomy & histology / Q000187:drug effects; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D043343:Testosterone Propionate / Q000031:analogs & derivatives / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D006063:Chorionic Gonadotropin; D005782:Gels; D013739:Testosterone; C035458:testosterone 17-phenylpropionate; C041677:testosterone decanoate; D043343:Testosterone Propionate; C086826:testosterone isocaproate